Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARO-ATXN2 in Adult Subjects With Spinocerebellar Ataxia Type 2
NCT06672445Phase 1Active, not recruiting
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 8
01
Overview
Phase 1, randomised trial in Spinocerebellar Ataxia Type 2 (SCA2) comparing ARO-ATXN2 with Placebo (2 arms). Primary endpoint: Treatment-Emergent Adverse Events at Day 253. Started Dec 2024; status: active, not recruiting.
02
Drugs
ARO-ATXN2
03
Conditions
Spinocerebellar Ataxia Type 2 (SCA2)
Beyond the preview
Go deeper on NCT06672445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06672445.